Dernières nouvelles

Information non disponible

15 enregistrements « 1 de 2 »

Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B

BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.

Article de revue

Br J Haematol, 2021.

Résumé | Liens:

Amitai I, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Chodirker L, Mozessohn L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R

Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.

Article de revue

Br J Haematol, 194 (2), 2021.

Résumé | Liens:

Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B

Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.

Article de revue

Br J Haematol, 193 (4), 2021.

Résumé | Liens:

Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N

Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.

Article de revue

Am J Hematol, 96 (6), 2021.

| Liens:

Wan BA, Nazha A, Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring J, Nevill TJ, Delage R, Elemary M, Banerji V, Parmentier A, Siddiqui M, Kirubananthaan A, Mamedov A, Zhang L, Buckstein R

Revised 15-item MDS-specific frailty scale maintains prognostic potential.

Article de revue

Leukemia, 34 (12), 2020.

| Liens:

Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R

An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.

Article de revue

Leukemia, 34 (5), 2020.

Résumé | Liens:

Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Article de revue

Cancer, 125 (4), 2019.

Résumé | Liens:

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Article de revue

Leuk Res, 74 , 2018.

Résumé | Liens:

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.

Article de revue

Br J Haematol, 179 (1), 2017.

Résumé | Liens:

Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R

A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.

Article de revue

Ann Hematol, 96 (12), 2017.

Résumé | Liens:

15 enregistrements « 1 de 2 »
Signaler des ajouts ou des modifications

Projets terminés récemment

  • Recherche clinique en hématologie et en oncologie , du 2019-09-03 au 2020-03-31
  • Recherche clinique en hématologie et en oncologie , du 2020-02-05 au 2020-03-31
  • Registre canadien de la LMC - The CML registry of the GQR-LMC, du 2013-12-10 au 2020-03-31
  • Registre non-interventionnel et sans médicament à l'étude portant sur les néoplasies myéloprolifératives, du 2015-05-12 au 2020-03-31
Information provenant du registre des projets de recherche de l'Université Laval